Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The 1500 mg (1.5 g) designation identifies the amount of material associated with the vial
Final Bridge eligibility is determined by your Medicare Part D plan's prior authorization based on clinician-documented diagnoses, current BMI, and plan-specific requirements
Initial Phase 3 results are expected from 2026 onward, with potential FDA approval somewhere in the 20262027 window if the data holds
Another future direction of utilising GLP-1/GIP/glucagon receptor triagonists is for MASH therapy with the rationale that as GLP-1 receptor agonists halt fibrosis progression, the new therapies might be able to enable fibrosis regression [11]
US$ 29.43
US$ 24.03
US$ 21.08
US$ 24.71
US$ 20.49
US$ 26.22
